Merideth Wendland, MD | Radiation Oncologist at WVCI Eugene

Merideth Wendland, MD

Radiation Oncologist

Merideth Wendland, MD | Radiation Oncologist at WVCI Eugene

Request an Appointment

Primary Location

520 Country Club Road
Eugene, Oregon 97401

Phone: 541-683-5001
Fax: 541-683-1422

Patient Care Philosophy

Dr. Merideth Wendland is committed to offering the highest-quality, most technologically-advanced cancer treatment available in the region.

“We take exceptional care of patients and their families, but also help guide and navigate them through the sometimes complex medical system,” she says.

Dr. Wendland brings her hope, respect and a penchant for collaboration and communication to work every day on behalf of her patients, as well as her experience and focus on advances in technology and patient-centered care.

She is the former national chairwoman of the US Oncology Network’s Neuro-Oncology Radiation Research Committee. 

Personal Information

Away from WVCI, Dr. Wendland is involved with a variety of charitable organizations, including Meals on Wheels and FOOD for Lane County. She enjoys hiking, kayaking, snowboarding and gardening.


University of Utah

Medical School

University of Washington School of Medicine


Sacred Heart Medical Center

Additional Information

Dr. Wendland's contributions to numerous clinical research trials for the treatment of CNS tumors can be found in the following peer reviewed journals: 

  • Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial 
  • NRG/RTOG 1122: phase II double-blinded, placebo-controlled study of bevacizumab with/without trebananib in patients with recurrent glioblastoma or gliosarcoma
  • RTOG 0913: A Phase I Study of Daily Everolimus (RAD001) In Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma
  • A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
  • The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy
  • Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)

What Satisfied Patients Are Saying About Dr. Wendland